TOKYO – Dec. 20, 2017 – JSR Life Sciences (JLS) announced today that JSR Corporation has agreed to purchase Crown Bioscience International (TPEx: ticker 6554) at 12 Billion New Taiwan Dollar, a global drug discovery and development services company providing translational platforms to advanced oncology, inflammation, cardiovascular and metabolic disease research.  This acquisition marks JSR’s largest life sciences-focused investment to date, extending the company’s portfolio to include industry-leading contract research and development capabilities

JSR Life Sciences, the life-sciences focused division of JSR Corporation, will offer industry partners best-in-class CDMO services by complementing its commercial subsidiary KBI Biopharma with Selexis SA Technologies

Durham, NC - May 23, 2017 - JSR Life Sciences (JLS) today announced that KBI Biopharma (KBI), a subsidiary of JSR Corporation (JSR), is expanding its biopharmaceutical manufacturing capacity and capabilities at both its Durham, North Carolina and Boulder, Colorado facilities.  KBI is investing approximately $30M on the two site expansion projects, which will greatly enhance the offerings at each site and are scheduled for completion later this year.